![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of Phase 2-3 Trials -2
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Zeuzem S1; Rockstroh J2; Kwo P3; Roth D4; Lawitz E5; Sulkowski M6;
Forns X7; Wahl J8; Robertson M8; Nguyen B-Y8; Barr E8; Howe A8*; Miller M8;
Hwang P8; Chen E8; Koury K8
1Goethe University Hospital, Frankfurt, Germany; 2Bonn University Hospital, Bonn, Germany; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4University of Miami Miller School of Medicine, Miami, FL, USA; 5The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 6Johns Hopkins University School of Medicine, Baltimore, MD, USA; 7Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain; 8Merck & Co., Inc., Kenilworth, NJ, USA. *Former employee of Merck & Co., Inc.
![HIV1.gif](../../2016/images/010816/010816-3/HIV1.gif)
![HIV2.gif](../../2016/images/010816/010816-3/HIV2.gif)
![HIV3.gif](../../2016/images/010816/010816-3/HIV3.gif)
![HIV4.gif](../../2016/images/010816/010816-3/HIV4.gif)
![HIV5.gif](../../2016/images/010816/010816-3/HIV5.gif)
![HIV6.gif](../../2016/images/010816/010816-3/HIV6.gif)
![HIV7.gif](../../2016/images/010816/010816-3/HIV7.gif)
![HIV8.gif](../../2016/images/010816/010816-3/HIV8.gif)
![HIV9.gif](../../2016/images/010816/010816-3/HIV9.gif)
![HIV10.gif](../../2016/images/010816/010816-3/HIV10.gif)
![HIV11.gif](../../2016/images/010816/010816-3/HIV11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|